How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria?

Current Hypertension Reports

Volumn 5, Issue 5, 2003, Pages 426-429

  Segura, Julian ^b   Christiansen, Helle ^b   Campo, Carlos ^b   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LOSARTAN; TRANDOLAPRIL; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DOSE CALCULATION; DRUG DOSE REGIMEN; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY INJURY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TITRIMETRY; URINARY EXCRETION; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; KIDNEY DISEASES; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0642373661     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0089-7     Document Type: Review

References (29)

1. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003, 289:2560-2571.
2. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
3. Ruilope LM, Schiffrin E: Blood pressure control and benefits of antihypertensive therapy: does it make a difference what agent we use? Hypertension 2001, 38:537-542.
4. Ruilope LM, Salvetti A, Jamerson K, et al.: Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001, 12:218-225.
5. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754-762.
6. Ruilope LM, Campo C, Rodicio JL: Blood pressure control, proteinuria and renal outcome in chronic renal failure. Curr Opin Nephrol Hypertens 1998, 7:145-148.
7. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002, 136:604-615.
8. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
9. Ritz E, Dikow R, Ruilope LM: Renal dysfunction as a cardiovascular risk factor. Curr Hypertens Rep 2002, 4:365-368.
10. Ruilope LM: The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002, 3:S165-S168.
11. De Leeuw P, Ruilope LM, Brown M, et al.: Clinical significance of renal function in high-risk hypertensive patients: results from the INSIGHT trial [submitted]. Hypertension 2003, In press.
12. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF: Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001, 38:1782-1787.
13. Parving HH, Mogensen CE, Jensen HA, Evrin PE: Increased urinary albumin-excretion rate in benign essential hypertension. Lancet 1974, 1:1190-1192.
14. Weidmann P, Boehlen LM, de Courten M: Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993, 8:582-584.
15. The PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002, 20:729-737.
16. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
17. Schrier R, McFann K, Johnsin A, et al.: Cardiac and renal effects of standard versus vigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomised study. J Am Soc Nephrol 2002, 13:1733-1739.
18. African American Study of Kidney Disease and Hypertension: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomised controlled trial. JAMA 2001, 285:2719-2728.
19. Weinberg AJ, Haneiwich R, Weinberg MS: The safety and efficacy of supramaximal doses of candesartan cilexetil (160 mg) in chronic renal disease patients' naïve to angiotensin receptor blockade therapy [abstract]. Am J Hypertens 2003, 16:103A.
20. Andersen S, Jacobsen P, Tarnow L, et al.: Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003, 18:293-297.
21. Laverman GD, Navis G, Henning RH, et al.: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62:1020-1025.
22. Segura J, Praga M, Campo C, et al.: Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 2003, 4:43-47.
23. Weinberg MS, Weinberg AJ, Zappe DH: Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2000, 1:217-233.
24. Andersen S, Rossing P, Juhl TR, et al.: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002, 17:1413-1418.
25. Rossing K, Christensen PK, Hansen BV, et al.: Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double blind randomised crossover study. Diabetes Care 2003, 26:150-155.
26. Epstein M, Buckalew V, Martinez F: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002, 15:57A.
27. Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
28. Raji A, Seely EW, Bekins SA, et al.: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26:172-178.
29. Bakris G, Viberti G, Weston WM, et al.: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003, 17:7-12.